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Abstract: The activity of microsomal cytochromes P450 (CYP) is strictly dependent on the supply
of electrons provided by NADPH cytochrome P450 oxidoreductase (CPR). The variant nature of
the isoform-specific proximal interface of microsomal CYPs implies that the interacting interface
between the two proteins is degenerated. Recently, we demonstrated that specific CPR mutations in
the FMN-domain (FD) may induce a gain in activity for a specific CYP isoform. In the current report,
we confirm the CYP isoform dependence of CPR’s degenerated binding by demonstrating that the
effect of four of the formerly studied FD mutants are indeed exclusive of a specific CYP isoform,
as verified by cytochrome c inhibition studies. Moreover, the nature of CYP’s substrate seems to have
a modulating role in the CPR:CYP interaction. In silico molecular dynamics simulations of the FD
evidence that mutations induces very subtle structural alterations, influencing the characteristics
of residues formerly implicated in the CPR:CYP interaction or in positioning of the FMN moiety.
CPR seems therefore to be able to form effective interaction complexes with its structural diverse
partners via a combination of specific structural features of the FD, which are functional in a CYP
isoform dependent manner, and dependent on the substrate bound.
Keywords: NADPH-cytochrome P450 reductase; microsomal cytochrome P450; CPR-FMN-domain;
protein–protein interaction; CYP-substrate; electron transfer
1. Introduction
Human mitochondrial and microsomal cytochromes P450 (CYP) form a superfamily of
membrane-bound hemeproteins with monooxygenase activity [1,2]. Microsomal CYP isoforms are
dependent on NADPH cytochrome P450 oxidoreductase (CPR)—containing flavin adenine dinucleotide
(FAD) (reductase) and flavin mononucleotide (FMN) (transporter) domains—for supply of electrons in
their catalytic activities to metabolize a myriad of compounds, both endobiotics including vitamins,
steroids and hormones, and xenobiotics, such as therapeutic drugs, carcinogens and environmental
chemicals [3–5].
The study of affinity and binding in the CPR:CYP microsomal monooxygenase system is crucial
for a better understanding of the structural features which guide the formation of an efficient enzyme
complex, determinant for electron transfer (ET) from CPR to CYP, thus potentially modulating
physiologically important microsomal CYPs activities. Although all CYPs are likely to diverge from
a common ancestor gene, their interactions with redox partners seem to have evolved differently,
depending on the cellular localization and type of substrates to metabolize [2,6]. Mitochondrial
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CYPs exhibit conserved basic residues at their proximal side for effective interaction with their
cognate redox partner: [2Fe-2S] adrenodoxin (Adx) [7]. Contrarily, microsomal CYPs do not possess
such signature sequences to guide their interaction with the FMN-domain (FD) of CPR for ET [6].
This suggests that CPR:CYP electron transport system is more versatile and does not depend on
uniquely conserved structural features present on CPR–CYPs interaction interface. Instead, it relies on
a degenerate interaction between the FD and the proximal side of the structurally diverse microsomal
CYP isoforms [6,8–10].
The precise mechanism governing this degenerated protein-protein interaction and how CPR can
sustain efficient ET with so many structurally diverse partners has been the subject of many studies
over the last decades (reviewed in [2,5,10]). The overall steady-state ET from CPR to microsomal CYPs
seems to occur via a concerted mechanism involving the FD and FAD-domain within CPR (inter-flavin
ET) and the FD and CYP proximal side (inter-protein ET) [3–5]. Multiple studies reported by our group
and others indicate that effective docking and ET from CPR to its many redox partners are enabled by:
(i) The existence of multiple open conformations, the result of CPR’s open-closed dynamics, that can be
sampled by its diverse redox partners [11–15]; and (ii) affinity probing of these open conformers, guided
by electron receptor specific affinity for the degenerated interface/binding site of CPR [6,8,9,16,17].
Together with the membrane anchoring segment, implicated in the preliminary association of the CPR
with CYPs and in substrate entrance/binding to CYP’s substrate-access channel [18–21], these features
are thus required for an effective ET by CPR to multiple CYPs.
However, these “one-serve-all” types of interactions may still be dependent on the CYP isoform.
It is likely that multiple CPR conformations and binding modes are probed in a selection process by
which each of the structurally diverse CYP isoforms binds to (a) more favorable conformation(s) of the
CPR [5]. Additionally, the in vivo existence of a vast excess of CYPs over CPR, implies competition
between individual CYP isoforms in binding to CPR. This evidences the role of affinity in the formation
of effective transient enzyme complexes, rather than stable complexes [11,22,23].
Through structural and functional studies, specific patches of acidic residues surrounding the flavin
isoalloxazine ring and on the binding interface of the FD were identified. These acidic residues drive
the effective docking between CPR and its multiple electron acceptors via electrostatic interactions
(Supplementary Figure S1) [14,17,24–26]. However, the relative importance of these residues for
interaction seems to be dependent on the CPR:redox-partner couple [2,5]. Additionally, basic residues
on the proximal side of CYPs seem to steer the negatively charged convex binding-interface of the
FD to CYP’s concave docking site near the heme moiety [9]. Interestingly, structural information on
CYP substrate/ligand complexes and conformational dynamics for substrate access demonstrated that
CYP’s active site adapts to substrates of diverse sizes and shapes, which in turn may have implications
in the CPR:CYP interaction as the structural rearrangement associated with substrate binding was
shown to extends its effects to the proximal side of CYPs [1,2,27–31].
We previously studied the underlying molecular mechanisms on CPR:CYP interaction and
ET, by creating and selecting seven mutants in the FD of human CPR, each supporting a gain in
activity for a specific CYP isoform [16]. Most of the identified positions co-localize with specific
acidic stretches—formerly indicated to be involved in CPR:CYP interactions—and/or with mutations
found in naturally occurring CPR variants—previously shown to cause CYP isoform dependent
effects [4,22,32–35]. The present study aims: (i) To explore CPR’s degenerated binding mode by
demonstrating that the generated FD mutants of CPR are exclusive of a specific CYP isoform and thus is
detrimental to interaction of CPR with other CYP forms; (ii) to determine the role of substrate-binding
in CYPs in modulating this specific recognition. From the set of previously identified CYP-specific
CPR mutants [16], we selected P117H and G144C (specific for CYP1A2), G175D (specific for CYP2A6)
and N151D (specific for CYP3A4) and crossed-combined each of them with the two other CYPs, i.e.,
the ones not used in their selection. Effects were evaluated using extended enzyme kinetic analysis
with different fluorogenic standard probes, cytochrome c (cyt c) competition, and multiple structural
(in silico) analyses. The results presented herein further confirm the preferential interaction of CYP
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isoforms with FD mutants and describe the structural features that promote the CPR–CYP recognition
in an isoform specific manner, thus potentially modulating CPR’s promiscuous interactions with
structurally diverse CYP isoforms and CYP-substrate binding states.
2. Results
2.1. Characterization of the Membrane Fractions
The characterization of contents of heterologous expressed proteins found in the membrane
fractions (isolated using the bacterial CPR/CYP co-expression system, BTC) [22,36] containing the
wildtype CPR (CPRwt) and mutant CPRs (CPRmut) combined with CYP1A2, 2A6 or 3A4 is shown
in Table 1. Co-expression of CPRmut with CYP1A2, 2A6, or 3A4 was achieved with a stoichiometry
approximating the one obtained with CPRwt for each CYP, demonstrating no significant differences
(p > 0.05). As such, any difference detected in the CYP activities can be ascribed to differences in the
CPRmut:CYP coupling. Indeed, the CPR:CYP stoichiometries measured in membrane fractions were
similar to those described previously for the BTC system in our former studies [11,16,33,36–39], and
comparable with the ranges of those reported for human liver microsomes, which range from 1:2 to
1:13 [40,41]. These ratios evidence a submolar presence of CPR vs. CYP, which is recapitulated in the
BTC system, as already demonstrated in our former studies [11,22,36,39].
Table 1. Cytochromes P450 (CYP) and cytochrome P450 oxidoreductase (CPR) contents of bacterial
CPR/CYP co-expression system (BTC) membrane fractions.






(pmol/mg Protein) Ratios a
CYP1A2
wt a 54 ± 1 4.1 ± 1.5 1:13
P117H b 148 ± 1 12.2 ± 0.5 1:12
G144C b 124 ± 2 14.1 ± 0.2 1:9
G175D 379 ± 2 26.5 ± 0.4 1:14
N151D 446 ± 4 27.7 ± 0.5 1:16
CPRnull b 91 ± 6 NA NA
CYP2A6
wt b 139 ± 1 10.5 ± 1.3 1:13
P117H 205 ± 3 16.5 ± 0.9 1:12
G144C 315 ± 8 28.3 ± 0.8 1:11
G175D b 112 ± 6 11.3 ± 0.5 1:10
N151D 221 ± 1 19.7 ± 0.8 1:11
CPRnull b 178 ± 4 NA NA
CYP3A4
wt a 83 ± 3 19.8 ± 0.2 1:4
P117H 230 ± 9 35.5 ± 0.8 1:6
G144C 189 ± 11 26.5 ± 0.3 1:7
G175D 143 ± 5 31.5 ± 0.5 1:5
N151D b 45 ± 1 12.7 ± 0.6 1:4
CPRnull b 85 ± 3 NA NA
CYP and CPR contents are mean ± sd (technical replicates N = 3). Color code indicates the CYP isoform with which
the CPR-FMN-domain mutant was isolated (CYP1A2 green; CYP2A6: blue; CYP3A4: red). (NA) not applicable.
a Co-expression of CPRmut with CYPs was achieved with stoichiometry’s approximating those obtained with CPRwt.
CPR/CYP ratios of the CPRmut were not significantly different from the ones of the corresponding CPRwt (p > 0.05),
with each tested CYP. b Membrane fractions and values from batches used in our former studies [11,16].
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2.2. Detailed Enzyme Activity
2.2.1. Reaction Velocities of the Different CPRmut:CYP Combinations
Comparison of the kinetic parameters for each CPRmut/CYP couple are presented in Figure 1 and
detailed numbers in Supplementary Table S1. We confirm the significantly higher relative turnovers of
these mutants in combination with specific CYPs, namely CPRP117H:CYP1A2 and CPRG144C:CYP1A2
[ethoxyresorufin (EthR) O-deethylation, EROD], CPRG175D:CYP2A6 (coumarin 7-hydroxylation, C7H)
and CPRN151D:CYP3A4 [dibenzylfluorescein (DBF) O-debenzylation, DBODF], as was observed in
our previous study [16]. Except for CPRG175D:CYP3A4 (increased kcat, 1.22 X, p < 0.005) (Figure 1C),
all the new CPRmut:CYP combinations demonstrated equal (CPRP117H:CYP2A6; CPRN151D:CYP2A6)
or significantly lower activities (CPRG175D:CYP1A2; CPRN151D:CYP1A2; CPRG144C:CYP2A6;
CPRP117H:CYP3A4; CPRG144C:CYP3A4) when compared to the corresponding CPRwt:CYP couples.
According to this data, one single mutation in the FD is able to induce increased ET efficiency for
one specific CPR:CYP combination, while maintaining or decreasing this activity for other couples.
In few cases, the apparent affinity constant (KM) changed with the FD mutant CPRs. The apparent
affinity constant of the CYP enzyme complex is a combination of multiple factors such as substrate
entrance, binding and product egress but also ET rates. We thus hypothesize that mutations in the
FD, by either affecting the binding of CPR to CYPs or directly modifying ET, may affect the apparent
affinity constants.
2.2.2. Reaction Velocities of CPRmut:CYP1A2 Using Different Substrates
Microsomal CYP turn-overs can be modulated by many parameters and, amongst those,
the efficiency of the complex formation between CPR and CYP and the substrate nature and presence
in the active site are known to be critical [5,42]. We thus compared the effects of the four FD
mutations of CPR with CYP1A2 using two other substrates (Figure 2 and Supplementary Table S2).
Globally, the effects of the mutations are substrate dependent: The relative kcat profiles observed
for the CPRmut:CYP1A2 in [3-cyano-7-ethoxycoumarin (CEC) O-dealkylation, CECOD] (Figure 2A)
and DBODF (Figure 2B) are distinct from the ones of EROD. Contrarily to the activity profiles
observed for EROD (Figure 1A, i.e., increased CYP1A2 activity with P117H and G144C; p < 0.005),
the kcat of CYP1A2 generated with these CPR mutants demonstrated CPRwt-like profiles for CECOD
(Figure 2A) and DBODF (Figure 2B). The G175D mutant (selected previously for increased CYP2A6-C7H
activity) showed a decrease in CYP1A2-EROD (p < 0.05) and -CECOD (p < 0.05) activities, when
compared with the CPRwt. Inversely, this mutant increased considerably the CYP1A2-DBODF activity
(p < 0.005). A decrease in CYP1A2-EROD (p < 0.005) and -CECOD (p < 0.005) activities and a CPRwt-like
CYP1A2-DBODF activity were observed for the N151D mutant (selected previously for increased
CYP3A4-DBODF activity).
When comparing the relative kcat profiles of the different reactions, DBODF, a typical CYP3A4
substrate, showed turnover profiles (Figure 2B) distinct from the other substrates studied. This may
be explained by DBF’s less favorable chemical structure, when compared to the other, more typical
CYP1A2 substrates studied. P117H, G144C and N151D demonstrated relative DBODF turnovers very
similar to the ones of CPRwt:CYP1A2, while for G175D we observed a completely different pattern.
For this specific mutant, relative kcat values increased dramatically (1.83 X, p < 0.005). This was not
observed, either for the other two substrates or by any of the other CPRmut:CYP1A2 combinations.
Additionally, the CPRmut:CYP1A2 reaction velocities profiles for the CYP1A2 mediated de-alkylation
of methoxyresorufine (MROD) (Supplementary Figure S2) were identical to the ones observed for the
EROD reaction. These results are not surprising because substrates (typical CYP1A2 substrates) are
similar and deviate only by one CH2 group.
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Figure 1. Relative turnover rates (kcat) (x fold) of the CPRmut:CYP1A2 EROD (A), C Rmut:CYP2A6
C7H (B), and CPRmut:CYP3A4 DBODF (C) activities, normalized by the kcat demonstrated by
CPRwt/CYP (determined in membrane fractions; technical replicates N = 3). CPR-FMN-domain
wildtype (CPRwt:CYP, black stripes). CPR-FMN-domain mutants previously demonstrated to support
a gain in CYP1A2-mediated EROD- (P117H and G144C: green), CYP2A6-mediated C7H- (G175D: blue),
and CYP3A4-mediated DBODF-activity (N151D: red). kcat values of the CPRmut/CYP were compared
with the ones of the CPRwt/CYP applying the unpaired t test (*** p < 0.0005; ** p < 0.005; * p < 0.05).
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replicates N = 3). CPR-FMN-domain wildtype (CPRwt:CYP, black stripes). CPR-FMN-domain
mutants previously demonstrated to support a gain in CYP1A2-mediated EROD- (P117H and G144C,
green), CYP2A6-mediated C7H- (G175D, blue), and CYP3A4-mediated DBODF-activity (N151D, red).
kcat values of the CPRmut/CYP1A2 were compared with the ones of the CPRwt/CYP1A2 applying the
un aired t t st (** p < 0.005; * p < 0. 5).
2.3. Cytochrome c Competition with CPRmut/CYP
In two recent studies, we applied cytochrome b5 (CYB5) to probe affinity differences between
CPR mutants and CYP [11,16]. Although informative, the inhibition data were difficult to interpret
due to a dual effect by CYB5, namely an initial stimulating effect on CYP activity (depending on
the CYP-isoform) and subsequent inhibitory effects at higher CYB5 levels when CPR binding is
prevented [16]. An alternative competitive inhibitor is cyt c. Structural and functional studies
of the FD binding site of rat CPR evidenced that the surface patches involved in protein:protein
contacts with both CYP and cyt c are probably overlapping (detailed in Supplementary Table S3,
and Figures S1 and S3) [5,14,17,24,25,43–48]. Therefore, cyt c competition experiments may shed
light on differences in affinity between the various FD mutants when binding to different CYPs,
without any confounding stimulatory effects when CYB5 is applied for this purpose. Relative
velocities (kobs mutant/kobs wild-type) were determined for the four FD mutants with various cyt
c/CPR ratios for CYP1A2, 2A6, or 3A4-mediated reactions (Figure 3). Globally, cyt c seems to have
an inhibitory effect on CYP dependent reactions, suggesting direct competition between cyt c and
CYP for CPR binding. The relative velocity traces of the CPRmut:CYP couples CPRP117H:CYP1A2,
CPRG144C:CYP1A2, CPRG175D:CYP2A6 and CPRN151D:CYP3A4 show less inhibited activities than those
from the corresponding CPRwt/CYP couples. Except for CPRN151D:CYP2A6 (Figure 3B), which showed
a pronounced inhibition by cyt c, the profiles of all other CPRmut:CYP couples were comparable to the
ones observed for the CPRwt:CYP. One-way analysis of variance demonstrated significant differences
(p < 0.05) between the distribution profile of the means of the activity traces of CPR:CYP1A2 (Figure 3A)
and CPR:CYP2A6 (Figure 3B) couples.
These results confirm that the competition exerted by cyt c with CYP for CPR-binding (i.e., ability
to inhibit CPR:CYP interaction and ET) depends on the strength of interaction between CPR and a
particular CYP, thus reinforcing the notion that the four mutants have indeed increased affinities for
the CYP with which they were selected. It is also most probable that the level of ionic interactions in
the CPR:CYP complex are CYP isoform dependent, which our former study demonstrated [11,16] and
current data confirmed.
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2.4. Structural Analysis of CPR Mutants
In order to interpret the biochemical properties of the mutants with structural modifications, we
performed molecular dynamics simulations. Four independent simulations were run for the wild-type
and each of the mutants, in water, during 80 ns. A first analysis of root mean square deviations (RMSD)
along the progress of the simulations revealed a common pattern: A rise in the RMSD in the first 20 ns,
corresponding to an increase in the energy as the starting coordinates were directly issued from a crystal
structure and then a stabilization of the RMSD corresponding to a stable energy state, with rather small
variations between the different simulations (Supplementary Figures S4 and S5). Comparisons of the
average structures from the simulations with the FMN domain from the crystal structure reveals minor
deviations which mostly affect helix A of the FMN domain. This helix, located at the N-terminus, is
probably more subjected to translation movements compared to the rest of the structure. In one of the
simulations (P117H, simulation 1), the time to reach the energy equilibrium is longer (40 ns instead of
~20 ns). In the average structure from this simulation, the D helix is slightly tilted toward the solvent.
The average RMSD value for N151D in simulation 3 is also slightly higher, which might reflect a larger
deviation from the starting structure. However, for both forms and simulations, the distribution of
RMSD after the equilibrium is similar to the others, implying that the equilibrium, when reached,
was the same for both particular simulations. In any case, the strongest deviations in RMSDs do not
cluster (albeit possibly for P117H simulation) close to the mutated positions (Supplementary Figure S5).
Therefore, the various selected mutations do not, in an 80 ns simulation, perturb the overall structure
or folding of the FD, but probably have rather specific and localized effects. We thus looked more
closely into the different simulations in order to reveal these localized effects and link them to known
properties for interactions between CPR and CYPs.
We first examined the effects of P117H and N151D mutations (Figure 4) on the pKa of acidic
residues around both positions. For P117H, the presence of a histidine at the position 117 leads to a
drastic change of the pKa of D116 and E118, but not E119 (Figure 4A). This change can be explained by
the short distances between the ND1 (tele or τ in IUPAC numbering) atom of H117 and the oxygen
atoms of the carboxylic functions of either D116 in simulation 1 and 4 (Supplementary Figure S6A)
or E118 in simulation 2, 3, and 4 (Supplementary Figure S6B), leading to potential hydrogen bonds
in both simulations (Supplementary Figure S6C). This difference between the two simulations is
interesting as it reveals the two possible states of the sidechain of H117 which may be interchanged in
longer simulations times. In any case, these changes propagate to the electrostatic potential which
is less negatively charged in the H117 simulations than the one present in the wild-type simulations
(Figure 4B). On the contrary, the presence of an aspartate residue instead of an asparagine at position
151 does not seem to modify the pKa of the surrounding acidic residues (Figure 4C). However,
the pKa of D151, while being one pH unit higher than the theoretical value of aspartate (Figure 4C),
introduces a supplementary negative charge in this area (Supplementary Figure S7). This is also
reflected on the electrostatic potential (Figure 4D), where, contrarily to P117H mutant (Figure 4B),
the added negative charge leads to a quite visible increase of the negative potential in the same region.
Overall, both mutations affect the electrostatic potential of the exact same area, although in a complete
opposite way, decreasing the charge density for P117H and increasing the negative potential for N151D.
Interestingly, D116 and E118 were formerly identified to be involved in hydrogen bonds with R440
in a docking model of the human FD of CPR with CYP2D6 [49,50]. Furthermore, a mutation of this
arginine residue into histidine leads to a 5- to 100-fold decrease of CYP2D6 activity [49].
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For G114C mutation, the situation is quite different as the glycine residue at this position in CPR is
well conserved amongst species. As seen in Figure 5A, the cysteine at this position extends toward the
surface but does not seem to perturb the positions of the residues surrounding the FMN moiety except
for E145 for which the sidechain moves backward to the FMN. Analysis of the pKa of the ionizable
residues close to the FMN (E145, E182 and H183) reveals no significant modifications compared to
the wild-type (Supplementary Figure S8). A more detailed analysis of the positioning of the FMN
in this pocket (Supplementary Figure S9) shows slight modifications of certain distances: Longer
average distances between the OH atom of Y143 or the N atom of C144 (vs. G144) and the C7M or
C8M atoms of FMN in the G144C mutant compared to the wild-type, longer distances between the
CG2 of V191 and C7M, C8M, N3, and N5 atoms of FMN. We can thus conclude that the mutation
G144C modifies slightly the positioning of the FMN moiety, which, in return, may impact the redox
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potential and electron transfer properties of the cofactor. However, the most drastic change can be seen
on the electrostatic potential of the surface around the FMN (Figure 5B) which is much less negative
than in the wild-type, due to probably both the movement of the E145 sidechain and the presence of
the sulfur atom of C144 around. Such a change can also affect the redox potential of the FMN cofactor
but also the positioning of the whole FD within the complex with CYPs.
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Quite surprisingly, for the G175D mutant (Figure 5C,D), the addition of an acidic residue on
β-strand 3 [45] does not modify drastically the structure of this region. The D175 residue is fully
embedded in the structure and its modelled pKa value (~9.0) is more than 5 pH units higher than
the theoretical value for aspartate residues (3.8), a quite logical value considering the total absence
of water molecules surrounding this aspartate. Consequently, the presence of an aspartate does not
modify the electrostatic potential around the mutated position. However, the OD1 atom of D175 is at
~3.1 Å of the N atom of T142 strongly suggesting that a hydrogen bond between β-strand 4 and α-helix
E may be created. Analysis of the various ϕ and ψ angles for β-strands 3 and 4 shows little effects
of the mutation on the overall secondary structures around the mutation position (Supplementary
Figure S10). The average ϕ angle value of D175 is smaller (Supplementary Figures S10, blue arrows
and S11), demonstrating a small but visible distortion of the β-strand 3 (Figure 5D, green for WT,
magenta for G175D). This is also reflected in the average ϕ values for A141 and M140 (Supplementary
Figure S10, red arrows) where the changes of the average ϕ angle value are a bit smaller or bigger
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(respectively) than for D175. Furthermore, for A141, the deviations around the average ϕ values are
bigger than for the wild-type, suggesting more flexibility at the end of the β-strand 4 (Supplementary
Figure S11). These changes impacted the residues surrounding the FMN moiety: The average distances
from the OH atom from Y143 and N atom of G144 to the C7M and C8M atoms of FMN were increased
(Supplementary Figure S12). Overall, the effects introduced by 3 of the analysed mutations (P117H,
G144C, N151D) lead to visible electrostatic surface changes, while, for the G175D mutation, no changes
in the electrostatic could be detected but possible changes in the mobility of the residues around the
FMN moiety are likely to occur.
3. Discussion
ET between CPR and its partners are mediated by weak and transient complexes that are highly
dynamic [5,42] and can be described as an ensemble of various protein orientations rapidly interchanging
between themselves [44]. Formation of these complexes is mainly guided by long-range electrostatic
interactions between complementary charges on the interacting surfaces [5,14,24,25,31,43,45,46].
Several studies questioned the role of specific residues of the FD of CPR in the complex formation,
either using site-specific modifications [3,14,17] or from analysis of naturally occurring variants of
CPR (reviewed in [4,32]). In a previous study [16], we demonstrated that selected FD mutations can
increase individual CYP isoforms activities. In the present study, we questioned the specificity of
four (P117H, G144C, N151D, and G175D) of the previously generated mutations toward CYPs by
analyzing the effect of each individual mutation on the three other CYPs and using different substrates.
As expected, the majority of those mutations had either no or detrimental effects when tested with
other CYP isoforms and can thus be considered CYP specific. It is known that CPR can interact with
distinct CYPs and promote ET to several isoforms simultaneously. Our data underpin the notion that
these “degenerated” interactions can be modulated by specific positions of the FD, increasing the
interactions of CPR with a specific CYP while, at the same time, decreasing the formation of interacting
complexes with other CYPs.
However, surprisingly, in the case of the CYP1A2, mutations that had negative effects with EROD
and CECOD had neutral (N151D) or enhancing effects (G175D) when DBODF was used as substrate.
This implies that the structural determinants present in the proximal side of CYPs can be modulated
by the type of substrate, which, in return, may change CPR:CYP interactions, potentially annihilating
the specific effects of the FD specific mutations. Moreover, the G175D mutant, selected previously for
increased CYP2A6-C7H activity, also improved significantly CYP3A4-DBODF activities. The positive
and pleiotropic effect of the G175D mutation was not observed with any of the other mutants but
occurred for two of the substrates studied (coumarin and DBF). Therefore, binding of these substrates
in different CYP isoforms may provoke similar structural alterations which then lead to better complex
formation with the G175D FD mutant.
The inhibitory effect of cyt c on CYP dependent reactions confirmed the existence of coinciding
conserved patches of acidic residues of CPR in its interaction with CYP and cyt c. The requirement for
relatively high cyt c/CPR ratios to observe this effect indicates that the affinity of CPR for CYP is higher
than that of CPR for cyt c. Our data also demonstrated that the amplitude of the cyt c effect is distinct
for each CPR variant studied. Furthermore, the inhibition by cyt c is less effective with all CPRmut
previously reported to support a gain in activity for the CYP they were isolated when compared with
CPRwt. Overall, our results confirm that the strengths of interactions between CYP isoforms and CPR
are probably different, as suggested in our previous studies [11,16,18].
Structural effects of the four mutations were analyzed via molecular dynamics simulations.
None of them affected drastically the stability or the secondary structures of the FD, in line with
the facts that the effects of the mutations were quite specific and the effects measured rather small.
Both P117H and N151D affect the electrostatic potential of the surface of the FD, albeit with opposite
effects: While the histidine residue in P117H, by being involved in hydrogen bonding with either
D116 or E117, slightly neutralizes the negatively charged surface, the presence of an aspartate in
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N151D, by adding a supplementary negative charge, increases the negative potential of the surface.
These conserved acidic patches (D116, E118 and E119) were formerly suggested to play a role in
CPR:CYP interactions [14,24,25,43,45,46], while the natural occurring variant A115V was shown to
have CYP-isoform dependent effects as well [35,51]. N151D is also in the vicinity of the naturally
occurring Q153R variant, a mutation linked with severely impaired steroidogenic activity, which
has been shown to have CYP isoform dependent effects as well [33,35,51]. Molecular docking also
demonstrated the existence of direct charge interactions between D116 and E118 of CPR with R440
of CYP2D6 [49,50]. Consequently, we hypothesize that the electrostatic potential around D116, E118,
and E119 may control the formation of specific contacts between CYPs and CPR and thus, mutations
that change the charge distribution modify the binding strength and impacts specifically some CYPs,
but not necessarily the others.
In position 144 lays the highly conserved glycine position (100%, among 1221 CPR sequences [16].
This residue is in the vicinity of the conserved acidic patch D147/150, adjacent to the conserved tyrosine
residue Y143 considered to be directly involved in FMN binding [26,52]. Additionally, G144 is located
close to T142, a position found mutated in a natural occurring variant (T142A), reported to lead to a
loss of activity in several CYPs, albeit in an isoform dependent manner [32,51]. Interestingly, while a
cysteine residue at this position does not promote major structural rearrangements, the presence of an
ionizable sulfur atom induces changes in the electrostatic potential around the FMN moiety. While we
do not rule out that such changes also affect the redox potential of the FMN cofactor, the less negative
electrostatic potential will also certainly modify the fine positioning of the FD into the CYP binding
site prior to ET.
Finally, for the G175D mutant, the aspartate residue, being completely hindered within the
structure, is almost non ionizable. However, the aspartate presence induces a small bending of β-strand
3, allowing for smallerϕ angle values for A141 (but with larger standard deviations around the average
value), impacting the fine positioning of the FMN cofactor.
4. Materials and Methods
4.1. Reagents
l-Arginine, thiamine, chloramphenicol, ampicillin, kanamycin sulfate, isopropyl
β-D-thiogalactoside (IPTG) (dioxane-free), δ-aminolevulinic acid, cytochrome c (horse heart), glucose
6-phosphate, glucose 6-phosphate dehydrogenase, nicotinamide adenine dinucleotide phosphate
(NADP+ and NADPH), resorufin, 7-hydroxy coumarin (7CH), 3-cyano-7-ethoxycoumarin (CEC),
and fluorescein were obtained from Sigma-Aldrich (St. Louis, MO, USA). LB Broth, bacto tryptone
and bacto peptone were purchased from BD Biosciences (San Jose, CA, USA). Bacto yeast extract
was obtained from Formedium (Norwich, UK). Ethoxyresorufin and coumarin were obtained from
BD Biosciences (San Jose, CA, USA) and dibenzylfluorescein from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). A polyclonal antibody from rabbit serum raised against recombinant human CPR
obtained from Genetex (Irvine, CA, USA) was used for immune-detection of the membrane-bound
CPR. All other chemicals and solvents were of the highest grade commercially available.
4.2. Membrane Fractions Preparation
The Escherichia coli cell model BTC was used for the heterologous co-expression of membrane-bound
human CYP isoforms (CYP1A2, 2A6 or 3A4) together with human full-length CPR, using a
biplasmid co-expression system, as previously reported [11,16,18,22,33,36,37]. CPR FD mutants
P117H, G144C, G175D, and N151D, harbored in the pLCM_POR plasmid were used to transform
E. coli PD301, already containing the expression vector (pCWori) for human CYP1A2, 2A6 or 3A4
(expressed in N-terminal modified forms), creating the following BTC strains: CPRP117H/CYP2A6,
CPRP117H/CYP3A4, CPRG144C/CYP2A6, CPRG144C/CYP3A4, CPRG175D/CYP1A2, CPRG175D/CYP3A4,
CPRN151D/CYP1A2, and CPRN151D/CYP2A6. Strains were cultured for heterologous expression
Int. J. Mol. Sci. 2020, 21, 6669 14 of 18
of the human proteins [33,37,38], and membrane fractions of the different strains were prepared
and characterized for total protein content (Bradford assay) as well as CYP- (CO-difference
spectrophotometry) and CPR- (immune-detection by Western blotting) contents, as described
previously [11,22,26,33,36–38].
4.3. CYP Enzyme Activity Assays
The catalytic activities of CYP1A2 (EROD), 2A6 (C7H), or 3A4 (DBODF), sustained by FD mutants
were evaluated as reported previously, using 0–5 µM EthR (CYP1A2), 0–20 µM coumarin (CYP2A6),
and 0–10 µM DBF (CYP3A4) [11,16]. When testing the effects of FD mutants in CYP1A2-activities
(CECOD and DBODF), the concentrations ranges were 0–50 µM CEC and 0–37.5 µM DBF. Initial
velocities were measured in triplicate and plots of velocity traces vs. substrates concentrations could
be fitted according to the Michaelis–Menten equation (r2 ≥ 0.95) to determine steady-state kinetic
parameters, using GraphPad Prism 5.01 Software (La Jolla, CA, USA) [22,33,38].
4.4. Cytochrome c Competition Assays
The effect of cyt c on CYP1A2, 2A6, or 3A4 activities, sustained by CPRwt and CPRmut, was assessed
using the same enzyme assay conditions as described above, except substrate concentrations were hold
constant (5 µM EthR, 20 µM coumarin or 7.5 µM DBF), and a gradient of cyt c (0–40 µM for CYP1A2
and 3A4, 0–50 µM for CYP2A6) was applied in 100 mM potassium phosphate buffer (pH 7.6), and
NADPH regenerating system (NADPH 200 µM, glucose 6-phosphate 500 µM and glucose 6-phosphate
dehydrogenase 40 U L−1, final concentrations). Velocities were measured in triplicate in 96-well format
using multi-mode microtiter plate reader (SpectraMax®i3x, Molecular Devices, USA; SoftMax Pro
2.0) [11,16]. All reaction velocities (kobs) were measured at least in triplicate [pmol of fluorescent
product formed/(pmol of CYP per minute)].
4.5. Structural Analysis of CPR Mutants
The structural analysis of the four mutants (P117H, G144C, N151D and G175D) was performed
using the CPR FD only, obtained from the crystal structure of human CPRwt (PDB 5FA6) as the starting
material. Mutations were constructed with the YASARA software (www.yasara.org). Fully hydrated
molecular dynamics simulations were performed for 80 ns using a step size of 100 ps with the Yasara
software suite using the AMBER14 force field at constant pressure (water density at 0.997 g/mL) and
temperature (298 K). Parameters were set as follows: Cuboid cell extending 10 nm on each side of the
protein, 0.9% NaCl and pH = 7.4. The Bio3D suite in R was used to calculate the coordinates of the
average structure from all snapshots, the root mean square deviations (RMSD), the various reported
distances and ϕ or ψ angles. Averages and standard deviations of the data was calculated with R. pKa
of ionizable residues were calculated from the average structures using the AMBER force-field and
the propka option of the pdb2pqr software at a pH of 7.5. Electrostatic potentials were calculated
on the average structures with the integrated module of the Pymol software (www.pymol.org) using
default parameters (non-linear Poisson-Boltzmann equation, protein dielectric 2.0, solvent dielectric
78.0, temperature 310 K, ion charge +1 of radius 2.0 Å and −1 of radius 1.8 both at 0.15 M) and plotted
on the solvent excluded surfaces (Connolly surfaces). Figures were prepared with the Pymol software
and R ggplot function. All modelling data is available upon request.
4.6. Statistical Analysis
Variance in data was analyzed through one-way ANOVA with Bonferroni’s multiple comparison
test. The unpaired Student t-test was performed for calculation of the two-tailed p value. The analysis
was performed with 95% confidence interval using the GraphPad Prism 5.01 Software. The significance
level considered in all the statistical tests was 0.05.
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5. Conclusions
Our data confirm and add additional evidences that CPR–CYP interactions are degenerated.
While the purpose of this degeneracy is evident as only one donor serves multiple partners (and
sometimes at the same time), it does not preclude the possibility of a gain of specificity, as demonstrated
by the effects of our selected FD mutations. It is noteworthy that both surfaces (CPR and CYP) can
be modified in order to get stronger interactions: Via mutations on the CPR side and via mutation
and/or substrate binding on the CYP side. This latter effect may well explain how, in situation when
specific CYP isoforms are metabolizing actively foreign or endogenous substrates, CPR could actually
distinguish between non active and active CYPs, thus rendering CYP metabolism more efficient
without any other transcriptional or posttranscriptional control, an elegant and efficient way to adjust
CYP oxidative activities.
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